Approach
How BridgeLine works
BridgeLine Translational is a translational strategy advisory led by Timothy Luongo, PhD. It works with biotech teams, investors, and partners across competitive intelligence, portfolio and indication strategy, preclinical strategy, and investor and partner readiness.
The practice
The firm reads the evidence behind a biotech program. Each program, tox package, dose rationale, and trial design is evaluated at protocol level, with the source trail attached.
The output is concrete. A landscape map a board can reference. A ranked indication or program list with the rationale behind it. A study-by-study development plan a CRO can quote against. An independent read on the package investors and partners are about to see. Scope shaped to the decision in front of the program, by one firm, in writing.
Values
Study-level specificity
Plans scoped to hand to a CRO or present to a board, not strategy slides with TBD timelines.
Constraints built in
Recommendations account for capital, calendar, and bandwidth constraints.
Gaps named in writing
Missing or weak sections are flagged in the deliverable.
Written recommendations
Written analysis with specific recommendations. No slideware.
Timothy is the principal of BridgeLine Translational. His career spans operator roles building IND-enabling programs and evaluator roles assessing them from the buy side. Most recently, he worked in External Innovation at Sarepta Therapeutics, evaluating acquisition and partnership opportunities and managing strategic collaborations across a broad range of therapeutic programs. Earlier, he led preclinical development and supported portfolio strategy at Spark Therapeutics (Roche) and StrideBio, advancing programs from discovery through IND-enabling studies.
Timothy holds a PhD in Molecular and Cellular Biosciences from Temple University and an MS in Translational Research from the University of Pennsylvania, specializing in Drug Development and Regulatory Affairs. He has authored over 20 publications in leading journals, including Nature, Cell, Immunity, and Circulation, and served on Penn's Institutional Review Board, reviewing clinical trial protocols.
The person scoping the work is the person doing the work.
§ / Engage
Contact
Share what you're working on. BridgeLine recommends the right place to start.